As previously reported, Guggenheim analyst Seamus Fernandez downgraded Sanofi (SNY) to Neutral from Buy and removed the firm’s previous price target on the shares. The firm had hoped to see materially improved pipeline-driven upside, but this “failed to materialize” and it now sees no thesis changing pipeline catalysts for at least the next 12 months, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi downgraded to Neutral from Buy at Guggenheim
- Sanofi downgraded to Neutral from Overweight at JPMorgan
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform
- FDA shift in drug study requirements sends trial runners lower